Last fall, FDA safety officers began compiling a list of children possibly killed by COVID vaccines. Digging through ...

A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...

Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 ...

Although ModernaMRNA initially established itself as a leading COVID-19 vaccine maker, the company is focused on broadening ...

The data were not bad — in fact, the outcome was better than many analysts had predicted. The problem was Cambridge-based ...